Switch theme
Sign up to access all valuation multiples
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
2012
153
LTM Revenue $111M
LTM EBITDA -$3.0M
$73.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Atara Biotherapeutics has a last 12-month revenue (LTM) of $111M and a last 12-month EBITDA of -$3.0M.
In the most recent fiscal year, Atara Biotherapeutics achieved revenue of $129M and an EBITDA of -$75.7M.
Atara Biotherapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Atara Biotherapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $111M | XXX | $129M | XXX | XXX | XXX |
| Gross Profit | $99.1M | XXX | $108M | XXX | XXX | XXX |
| Gross Margin | 89% | XXX | 84% | XXX | XXX | XXX |
| EBITDA | -$3.0M | XXX | -$75.7M | XXX | XXX | XXX |
| EBITDA Margin | -3% | XXX | -59% | XXX | XXX | XXX |
| EBIT | -$43.2M | XXX | -$83.4M | XXX | XXX | XXX |
| EBIT Margin | -39% | XXX | -65% | XXX | XXX | XXX |
| Net Profit | -$44.6M | XXX | -$85.4M | XXX | XXX | XXX |
| Net Margin | -40% | XXX | -66% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Atara Biotherapeutics's stock price is $8.
Atara Biotherapeutics has current market cap of $46.9M, and EV of $73.7M.
See Atara Biotherapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $73.7M | $46.9M | XXX | XXX | XXX | XXX | $-6.25 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Atara Biotherapeutics has market cap of $46.9M and EV of $73.7M.
Atara Biotherapeutics's trades at 0.6x EV/Revenue multiple, and -1.0x EV/EBITDA.
Equity research analysts estimate Atara Biotherapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Atara Biotherapeutics has a P/E ratio of -1.1x.
See valuation multiples for Atara Biotherapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $46.9M | XXX | $46.9M | XXX | XXX | XXX |
| EV (current) | $73.7M | XXX | $73.7M | XXX | XXX | XXX |
| EV/Revenue | 0.7x | XXX | 0.6x | XXX | XXX | XXX |
| EV/EBITDA | -24.8x | XXX | -1.0x | XXX | XXX | XXX |
| EV/EBIT | -1.7x | XXX | -0.9x | XXX | XXX | XXX |
| EV/Gross Profit | 0.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.1x | XXX | -0.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAtara Biotherapeutics's last 12 month revenue growth is -42%
Atara Biotherapeutics's revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $1.3M for the same period.
Atara Biotherapeutics's rule of 40 is -3145% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Atara Biotherapeutics's rule of X is -109% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Atara Biotherapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -42% | XXX | -50% | XXX | XXX | XXX |
| EBITDA Margin | -3% | XXX | -59% | XXX | XXX | XXX |
| EBITDA Growth | -581% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -3145% | XXX | -101% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -109% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 117% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 148% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Atara Biotherapeutics acquired XXX companies to date.
Last acquisition by Atara Biotherapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Atara Biotherapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Atara Biotherapeutics founded? | Atara Biotherapeutics was founded in 2012. |
| Where is Atara Biotherapeutics headquartered? | Atara Biotherapeutics is headquartered in United States of America. |
| How many employees does Atara Biotherapeutics have? | As of today, Atara Biotherapeutics has 153 employees. |
| Who is the CEO of Atara Biotherapeutics? | Atara Biotherapeutics's CEO is Dr. AnhCo Nguyen, PhD. |
| Is Atara Biotherapeutics publicy listed? | Yes, Atara Biotherapeutics is a public company listed on NAS. |
| What is the stock symbol of Atara Biotherapeutics? | Atara Biotherapeutics trades under ATRA ticker. |
| When did Atara Biotherapeutics go public? | Atara Biotherapeutics went public in 2014. |
| Who are competitors of Atara Biotherapeutics? | Similar companies to Atara Biotherapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Atara Biotherapeutics? | Atara Biotherapeutics's current market cap is $46.9M |
| What is the current revenue of Atara Biotherapeutics? | Atara Biotherapeutics's last 12 months revenue is $111M. |
| What is the current revenue growth of Atara Biotherapeutics? | Atara Biotherapeutics revenue growth (NTM/LTM) is -42%. |
| What is the current EV/Revenue multiple of Atara Biotherapeutics? | Current revenue multiple of Atara Biotherapeutics is 0.7x. |
| Is Atara Biotherapeutics profitable? | Yes, Atara Biotherapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Atara Biotherapeutics? | Atara Biotherapeutics's last 12 months EBITDA is -$3.0M. |
| What is Atara Biotherapeutics's EBITDA margin? | Atara Biotherapeutics's last 12 months EBITDA margin is -3%. |
| What is the current EV/EBITDA multiple of Atara Biotherapeutics? | Current EBITDA multiple of Atara Biotherapeutics is -24.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
